LYEL Lyell Immunopharma, Inc.
$9.28▼ -0.32%
Healthcare
Other
Volume 1.4K
Avg Volume (10D) 187.9K
Key Metrics & Fundamentals
Market Cap
$227.41M
P/E Ratio
–
Div Yield
0.00%
52W Range
7.20 - 45.00
% vs 50 MA
-18.08%
% vs 200 MA
-45.65%
RSI-14
46.0
MACD Histogram
+0.2800
Beta (1Y vs SPY)
1.41
Free Cash Flow
-$34.18M
Gross Rev
$4,000
Gross Profit
$4,000
EBITDA
-$45.12M
COGS
–
Operating Exp
$47.34M
Operating Income
-$47.34M
EBIT
-$47.34M
Pretax Income
-$44.76M
Net Income
-$44.76M
EPS (Diluted)
-1.92
Price & Volume History
Loading chart…
Recent News
Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
Zacks · Oct 13, 2026 8:35 AM ET
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
GlobeNewswire · Sep 14, 2026 7:00 AM ET
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
GlobeNewswire · Sep 10, 2026 4:05 PM ET
Lyell Immunopharma: Q2 Earnings Snapshot
Associated Press · Aug 6, 2026 5:39 PM ET
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
GlobeNewswire · Aug 6, 2026 4:05 PM ET
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
The Fly · Aug 6, 2026 9:48 AM ET
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
24/7 Wall St. · Aug 6, 2026 7:59 AM ET
Stifel Initiates Lyell Immunopharma at Buy With $36 Price Target
MT Newswires · Aug 6, 2026 7:18 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See LYEL's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.